These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26555483)

  • 1. Atorvastatin calcium encapsulated eudragit nanoparticles with enhanced oral bioavailability, safety and efficacy profile.
    Kumar N; Chaurasia S; Patel RR; Khan G; Kumar V; Mishra B
    Pharm Dev Technol; 2017 Mar; 22(2):156-167. PubMed ID: 26555483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and in vitro/in vivo evaluation of gliclazide loaded Eudragit nanoparticles as a sustained release carriers.
    Devarajan PV; Sonavane GS
    Drug Dev Ind Pharm; 2007 Feb; 33(2):101-11. PubMed ID: 17454041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-PK evaluation of freeze-dried atorvastatin calcium-loaded poly-ε-caprolactone nanoparticles.
    Ahmed IS; El-Hosary R; Shalaby S; Abd-Rabo MM; Elkhateeb DG; Nour S
    Int J Pharm; 2016 May; 504(1-2):70-9. PubMed ID: 27021467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of different types of nano drug delivery systems of atorvastatin for the treatment of hyperlipidemia.
    Mathur M; Devi Vemula K
    Drug Dev Ind Pharm; 2018 Dec; 44(12):2048-2060. PubMed ID: 30073852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia.
    Meena AK; Ratnam DV; Chandraiah G; Ankola DD; Rao PR; Kumar MN
    Lipids; 2008 Mar; 43(3):231-41. PubMed ID: 18196308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastroretentive bilayer film for sustained release of atorvastatin calcium and immediate release of amlodipine besylate: pharmaceutical, pharmacokinetic evaluation, and IVIVC.
    Porwal A; Dwivedi H; Pathak K
    Pharm Dev Technol; 2020 Apr; 25(4):416-431. PubMed ID: 31852330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems--enhancement of oral bioavailability.
    Hashem FM; Al-Sawahli MM; Nasr M; Ahmed OA
    Drug Des Devel Ther; 2015; 9():3141-52. PubMed ID: 26150693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulating Drug Release and Enhancing the Oral Bioavailability of Torcetrapib with Solid Lipid Dispersion Formulations.
    Liu Y; Salituro GM; Lee KJ; Bak A; Leung DH
    AAPS PharmSciTech; 2015 Oct; 16(5):1091-100. PubMed ID: 25690735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissolution enhancement of atorvastatin calcium by co-grinding technique.
    Prabhu P; Patravale V
    Drug Deliv Transl Res; 2016 Aug; 6(4):380-91. PubMed ID: 26712124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and characterization of metformin hydrochloride loaded-Eudragit®RSPO and Eudragit®RSPO/PLGA nanoparticles.
    Cetin M; Atila A; Sahin S; Vural I
    Pharm Dev Technol; 2013; 18(3):570-6. PubMed ID: 21864098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel genipin crosslinked atorvastatin loaded sericin nanoparticles for their enhanced antihyperlipidemic activity.
    Kanoujia J; Singh M; Singh P; Saraf SA
    Mater Sci Eng C Mater Biol Appl; 2016 Dec; 69():967-76. PubMed ID: 27612792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation.
    Khan S; Baboota S; Ali J; Narang RS; Narang JK
    Drug Dev Ind Pharm; 2016; 42(2):209-20. PubMed ID: 26016780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chitosan based atorvastatin nanocrystals: effect of cationic charge on particle size, formulation stability, and in-vivo efficacy.
    Kurakula M; El-Helw AM; Sobahi TR; Abdelaal MY
    Int J Nanomedicine; 2015; 10():321-34. PubMed ID: 25609947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro release of acyclovir loaded Eudragit RLPO(®) nanoparticles for sustained drug delivery.
    Gandhi A; Jana S; Sen KK
    Int J Biol Macromol; 2014 Jun; 67():478-82. PubMed ID: 24755259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silymarin-Loaded Eudragit Nanoparticles: Formulation, Characterization, and Hepatoprotective and Toxicity Evaluation.
    El-Nahas AE; Allam AN; Abdelmonsif DA; El-Kamel AH
    AAPS PharmSciTech; 2017 Nov; 18(8):3076-3086. PubMed ID: 28516410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiolated Eudragit nanoparticles for oral insulin delivery: preparation, characterization and in vivo evaluation.
    Zhang Y; Wu X; Meng L; Zhang Y; Ai R; Qi N; He H; Xu H; Tang X
    Int J Pharm; 2012 Oct; 436(1-2):341-50. PubMed ID: 22766443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atazanavir-loaded Eudragit RL 100 nanoparticles to improve oral bioavailability: optimization and in vitro/in vivo appraisal.
    Singh G; Pai RS
    Drug Deliv; 2016; 23(2):532-9. PubMed ID: 24963752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design.
    Dudhipala N; Veerabrahma K
    Drug Dev Ind Pharm; 2015; 41(12):1968-77. PubMed ID: 25830370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement.
    Mandpe L; Pokharkar V
    Pharm Dev Technol; 2015 May; 20(3):320-9. PubMed ID: 24328553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles.
    Suresh G; Manjunath K; Venkateswarlu V; Satyanarayana V
    AAPS PharmSciTech; 2007 Mar; 8(1):24. PubMed ID: 17408223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.